Are you facing challenges in quickly bringing new healthtech products to market? The NHS is a large and complex system and ...

Companies who receive scientific advice from our NICE Advice service may experience a faster path to guidance publication, a study has found.

The London School of Economics and Political Science (LSE) have joined forces with NICE to offer a unique solution - the Executive MSc in Healthcare Decision-Making.

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

Elafibranor (Iqirvo) is available on the NHS. It is a possible treatment for primary biliary cholangitis in adults, when used: with ursodeoxycholic acid (UDCA), if the condition has not responded well ...

The evaluation committee considered evidence submitted by Ipsen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

Review and download supporting evidence. Includes the full guideline if available.

alone, if UDCA cannot be tolerated. Elafibranor is only recommended if the company provides it according to the commercial arrangement.

Elafibranor (Iqirvo, Ipsen) is indicated for 'the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as ...

We use tools such as Google Analytics, Hotjar, Google Optimize and Loop11 to help us anonymously measure how you use our websites. This allows us to make improvements based on our users' needs.

There is a simple discount patient access scheme for elafibranor. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This procedure should only be done as part of a formal research study, and a research ethics committee needs to have approved its use.